Member Info for slock

amilia stone february 25, 2026 9:41 am

fundamental xr has launched immersive web, a platform designed to extend immersive training beyond headset-only environments and into the browser.

the company’s core proposition has centred on delivering high-fidelity, hands-on training through virtual environments. while immersive hardware enables realistic and repeatable skill development, full deployment can require logistical planning, capital investment and on-site coordination. immersive web introduces a browser-based layer that allows elements of training to be accessed without dedicated equipment, widening the potential user base and reducing friction at the point of entry.

this approach alters the economics of implementation. organisations can begin engagement through standard web browsers, enabling learners to complete preparatory modules, theoretical instruction and guided walkthroughs before progressing to fully immersive simulations. by separating foundational learning from advanced practical application, the platform supports a more staged investment model.

***************************/fundamental-xr-expands-access-to-immersive-training-with-web-enabled-platform/4121241298

I'd expect their reporting to be inline with all of their previous HY/FY, mainly focused on their own brands globally, with maybe a paragraph on Eroxon USA sales.

Further details could come via the Q&A if the analysts reference the product.

Futura Medical (FUM)

Having appeared in the “Top 5” in 2024 on high expectations for Eroxon following its EU and US regulatory approvals, FUM was the worst performer in 2025, with the shares falling 96%. Getting regulatory approval is one thing, converting this into commercial traction is a very different ball game. On the face of it, FUM had commercial agreements with strong consumer partners, notably Cooper Consumer Health (EU, UK and Switzerland) and Haleon (US). Despite this, Eroxon has failed to take off and consumer reviews on social media are extremely negative. It is difficult to see what will change this. FUM reported sales of £1.0m (vs. £3.8m) in 1H’25, and, in a trading statement issued in September, indicated that sales would reach only £1.3-£1.4m for the full year, indicating a very weak 2H’25. Interim results, also in September, showed that the company was very cash constrained and it was no surprise when FUM undertook a deeply-discounted emergency fundraise of £2.75m in November. New management is trying to recover the situation; ultimately, though, it requires strong endorsement for Eroxon from consumers, which seems highly unlikely, in our opinion. Also, we think that Haleon will almost certainly try and draw a line on this failed commercial venture in 2026 and, even though this might involve some financial compensation for FUM, it would leave the company with few options to improve shareholder value.

research-tree.com/research/hardman-co/hardman-co-healthcare-index-2025-index-rose-but-another-tough-year/13_daeccf67-41b5-459a-8b17-dbe98ddc26cf/4f624d4e-79b6-4f8b-a04d-9677aa628490

Not forgetting Haleons exposure in the China market. Reminder........

Haleon to increase stake in China JV to 88%

27 September 2024: Haleon plc ("Haleon") (LSE/NYSE: HLN) today announces that it has entered into an agreement to acquire an additional 33%1 equity interest in Tianjin TSKF Pharmaceutical Co. Ltd ("TSKF"), its joint venture in China from its partners, Tianjin Pharmaceutical Group ("TPG") and Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited ("DRTG") for a total consideration of RMB 4,465 million (c. £0.5 billion).

TSKF accounted for c. 40% of Haleon's China revenues in FY 2023 and manufactures and/or distributes leading brands such as Fenbid, Voltaren and Bactroban. This acquisition will increase Haleon's participation in TSKF from 55% to 88% and deliver greater control and increased strategic and operational flexibility across the business. The acquisition is expected to be funded through a combination of Haleon's existing cash resources and new third-party Renminbi-denominated debt. Subject to customary closing conditions, including the approval of DRTG's shareholders and applicable regulatory clearances, the transaction is expected to close end of 2024 and to be accretive to EPS.

In addition, Haleon and DRTG have agreed, effective from closing of the acquisition, that Haleon would have an option to acquire and DRTG an option to sell the remaining 12% shareholding in TSKF.

Brian McNamara, Chief Executive Officer of Haleon commented: "China is a key strategic market for Haleon. Over the last three years, it has delivered strong market share growth and our acquisition of a further 33% in our JV partnership is an important milestone which is both strategically and commercially compelling. It reflects our commitment to this important market, the exceptional growth potential we see in China and is fully consistent with our capital allocation priorities to drive attractive returns for shareholders and maintain a strong investment grade balance sheet."

Businesswire.com/news/home/20251212266703/en/Haleon-Recognized-by-Fast-Company-as-a-2025-Brands-That-Matter-Honoree

Dec 12, 2025 9:26 AM Eastern Standard Time

Haleon Recognized by Fast Company as a 2025 Brands That Matter Honoree

The subtle change that I refer to is in the 'About Haleon' section (below), found at the end of every RNS or Press release etc.

One of Haleons 6 major categories under which they account & report results on, has changed from "Therapeutic Skin Health and Other" to "Sexual Wellness", and they now also list Eroxon as one of their US brands which has never happened over the past 14 months since US launch.

My point is that whilst this may be a subtle change of wording, I do hope that it reflects a change in emphasis of Eroxon & future products to Haleon.

Additionally, Vitamins, Minerals and Supplements (VMS) category has also changed to "Wellness"

About Haleon

Haleon (NYSE: HLN) is a leading global consumer health company with a purpose to deliver better everyday health with Humanity. Haleon’s product portfolio spans six major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, Wellness, and Sexual Wellness. Built on trusted science, innovation, and deep human understanding, Haleon’s U.S. brands include Abreva, Advil, Benefiber, Centrum, Emergen-C, Eroxon, Excedrin, Flonase, Gas-X, Nexium, Nicorette, Parodontax, Polident, Preparation H, Pronamel, Sensodyne, Robitussin, Theraflu, TUMS, Voltaren, and more. For more information on Haleon and its brands, please visit haleon.com or contact USMediaRelations@haleon.com

businesswire.com/news/home/20251212266703/en/Haleon-Recognized-by-Fast-Company-as-a-2025-Brands-That-Matter-Honoree

Must be good news for FUM, if US sales improve (!)

bbc.co.uk/news/articles/cn0k520v4xro

As expected, no mention of Eroxon in the TU, nor during the 15 mins presentation, nor the 1hr Q&A. (which I'm not putting across as a negative, you have to understand that their Quarterly reporting is somewhat high level and focused on their main brands (which they own))

Skin Health Therapeutics & Other category, Q3 Rev £113 at group level, with double digit levels of growth seen in USA

USA total Q3 Rev £977m

They also commented that they see USA market returning to growth in 2026

In past years, their Q1 & Q3 TU's have been relatively high level, and from memory, have never even mentioned Eroxon as a product, never mind it's sales.

So, I'm not expecting much from them tomorrow. Best to hope for is a mention during the analyst Q&A

But, there could be an indicator from the sector revenues. Skin Health Therapeutics & Other category (which I am assuming is where Eroxon would sit, under Other) has grown revs over the past 3 quarters :

Q4 £108m

Q1 £117m

Q2 £132m

USA total revenue is the other obvious indicator

Q1 £980m

Q2 £871m

So, hopefully, the Other category continues it's growth, and USA total revs recover.

Music.youtube.com/podcast/CPP0wamcNls

The operating room isn’t the place to practice. At Fundamental XR, surgeons and clinicians gain experience before ever stepping inside one. Co-founded by CEO Richard Vincent, the company uses virtual, augmented, and mixed reality—combined with haptic feedback—to replicate the feel and precision of real procedures. Its goal: build the equivalent of a “flight simulator for surgeons.”

Through partnerships with medical device and pharmaceutical companies, Fundamental XR delivers scalable, measurable training to institutions across more than 35 countries. Over 75,000 procedures have been performed through its platform, spanning 20 surgical disciplines from orthopedics to ophthalmology. Each simulation captures sub-millimeter motion data to assess technique, guide improvement, and accelerate skill acquisition.

Vincent sees this as the first step toward what he calls “pre-human competence”—a future where no one learns on a live patient, and every clinician walks into the operating room fully prepared to perform.

They posted exactly the same 09th September when the price was 9.36p at close !!!!

Futura Medical (AIM:FUM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Futura Medical plc researches, develops, and commercializes pharmaceutical and healthcare products for sexual health, with a market cap of £7.60 million.

Operations: The company's revenue is primarily derived from the development and commercialization of MED3000, amounting to £7.93 million.

Market Cap: £7.6M

Futura Medical plc, with a market cap of £7.60 million, faces challenges as it transitions through a period of financial instability. Recent earnings reported for the half year ended June 30, 2025, showed sales of £1 million and a net loss of £6.59 million. The company's revenue guidance for the full year has been significantly lowered to between £1.3 million and £1.4 million due to slower sales across markets and delayed US patent payments. Despite being debt-free with strong short-term asset coverage over liabilities and an experienced management team, Futura remains unprofitable with high share price volatility recently observed.

simplywall.st/stocks/gb/consumer-services/lse-ptec/playtech-shares/news/top-uk-penny-stocks-to-watch-in-october-2025-1/amp

Fundamental XR has announced the launch of its Anatomy Inference Engine (AIE) BETA, a breakthrough AI-powered platform that the company says can generate realistic simulation ready 3D anatomical models in minutes.

Traditionally, building accurate anatomical models has required weeks of manual work, specialised teams, and costly resources. AIE changes this paradigm by using advanced AI pipelines trained on imaging data, surgical videos, and pathology datasets to instantly produce parameterised 3D anatomy with infinite variability.

Starting with the liver and soon to expand to other organs including the heart, lungs and kidneys, AIE enables simulation developers, educators, and researchers to input key parameters and generate anatomies at unprecedented speed and scale.

“Dynamic, variable anatomy is the backbone of medical simulation and healthcare R&D,” said Richard Vincent, Founder and CEO of Fundamental XR. “The Anatomy Inference Engine removes one of the biggest barriers to innovation by reducing creation time from weeks to moments. This doesn’t just accelerate time-to-market for education and training, it potentially opens new frontiers for clinical trials, synthetic datasets, and medical device development.

The AIE generates a complete 3D anatomical model that reflects the chosen inputs, including form, texture, and pathology. FXR says what once took weeks of expert modelling can now be achieved ‘instantly’.

“The ability to generate accurate, patient-specific anatomy in minutes is a true game changer,” continued Vincent. “We’re standing at a new frontier in healthcare innovation; one where synthetic data and infinite anatomical variability can accelerate progress in ways we may not even know yet.

“The Anatomy Inference Engine is a powerful new tool, and I’m excited to see how the industry will harness it to advance education, clinical trials, and medical device development.”

The Fundamental XR Anatomy Inference Engine (AIE) is now available in BETA.

med-techinsights.com/2025/10/22/fundamental-xr-launches-ai-powered-3d-anatomy-generation/

No new news, and noted that Allenby are broker & nomad to TERN

wp-allenby-2020.s3.eu-west-2.amazonaws.com/media/2025/10/Allenby-Capital-TMT-Update-13.10.25-NWT.L-TERN.L.pdf?c4988=on

Tern plc* (TERN.L, 0.525p/£3.4m)

Update: Cost reductions and new management incentives (09.10.25)

• Tern has introduced a new remuneration package for the board and executive team with a 50% reduction in

the salaries of the two Board directors and two executive managers. This will provide a saving of c. £153k per

annum. In addition to the reduced salary, the board and executive team will receive 12.5% of the net

proceeds of any exit of the Company's investments.

• Shareholders will receive a distribution or capital return of at least 50% of the net proceeds received from the

exit of any individual investment over £1m (subject to sufficient distributable reserves and no legal or

regulatory impediment).

• In September, the company announced an Open Offer at 0.5p/share, a 20% discount, on the basis of one

share for every five held to raise up to £0.6m. The Offer is open until 14 October.

Allenby Capital comment: Although the salary reduction will only have a limited impact on Tern's operating cost base, it

signals the alignment of the interests of the board and executive management with shareholders. Tern remains focused on

realisations in its portfolio of investments.

More trade press androidguys.com/news/fundamental-xr-introduces-fundamental-touch-a-new-dimension-in-wireless-haptics/

Fundamental Touch is set to revolutionize human-machine interactions across various sectors, opening up new possibilities where touch and simulated sensations are key:

Industrial Training & Education: Scalable wireless haptic training supports immersive learning, enabling practice of complex tasks in safe, dynamic environments.

Robotics & Remote Operations: Operators can experience what a robot feels, enhancing control in hazardous locations like nuclear facilities or space.

Search & Rescue: Tactile feedback aids operations in challenging conditions with low visibility.

Military & Defense: Wireless haptics improve safety and precision in tasks like explosive ordnance disposal and hazardous material handling.

Gaming & Simulation: By supporting wireless headsets and haptic-enabled hardware, Fundamental Touch delivers realism in cloud and VR gaming, making gameplay more accessible and true-to-life.

Automotive & Mobility: Driver training simulators and vehicle teleoperation benefit from enhanced realism and responsiveness.

Aerospace & Aviation: From pilot simulators to robotic spacecraft control, wireless haptics provide lifelike sensations needed in high-stakes scenarios.

Arts, Design & Creative Industries: Tactile interaction in digital sculpting and 3D modeling allows creators to experience textures and forms before production.

By The Robot Report Staff | October 9, 2025

Tactile feedback could be useful in multiple applications, but the sensors traditionally require tethers. Fundamental XR today announced the availability of Fundamental Touch, a wireless platform brining haptics beyond healthcare into industries including robotics, industrial training, automotive, aerospace, retail, and gaming.

“Touch is the missing dimension in human–machine interaction, and precision kinesthetic haptics finally unlocks its full potential by going wireless,” said Richard Vincent, founder and CEO of Fundamental XR. “Fundamental Touch removes the physical tether, giving users the mobility and performance parity they need to train, explore, and operate in ways never before possible.”

Fundamental XR said its immersive technologies including augmented, mixed, and virtual reality (AR/MR/VR), haptics, web, and app to help medical teams train and adopt complex procedures. The London-based company, formerly known as FundamentalVR, claimed that its platform can reduce onboarding time by more than 60%, boost surgical accuracy by 44%, and increase sales performance by 22%.

Fundamental XR said healthcare organizations use its spatial technologies to “accelerate skill acquisition, improve outcomes, and power the next generation of digital surgery.” They have delivered more than 50,000 sessions in over 30 countries, it added

therobotreport.com/fundamental-xr-launches-fundamental-touch-for-wireless-haptics/

NATIONAL REPORT — The health and beauty care (HBC) category in convenience stores is growing in 2025, but is being led by some less traditional segments, according to industry insiders.

From January through June, almost all segments of HBC were down in unit volume year over year, but up in dollar sales due to inflation. One exception was the vitamins and supplements segment, which experienced a 4.9% increase in unit volume and a 9.5% increase in dollar sales industrywide, according to sales data from Chicago-based market researcher NIQ.

Doug Middlebrooks, senior vice president of convenience channel sales for Advantage Solutions, an omnichannel retail solutions agency in North America that's positioned at the intersection of consumer packaged goods brands and retailers, confirms that vitamins and supplements are "showing significant growth in the channel." Other segments that he says are performing well this year are sexual health products and first aid treatments.

The family planning and sexual health segment is "a standout segment which has seen accelerated growth," echoes Ryan Lutes, senior manager of analytics and insights at Lil' Drug Store Products, which offers category management solutions to c-store retailers and wholesalers. According to Lutes, the Morning After Pill emergency contraceptive from Cadence OTC is the predominant growth driver in this segment.

"It is an item that's bringing critical access to a channel that historically lacked it," he said. "With new [over-the-counter] innovations like Haleon's Eroxon, an erectile dysfunction treatment gel, and the increasing availability of over-the-counter birth control, this category is poised for continued momentum in convenience."

csnews.com/sales-nontraditional-products-fuel-hbc-growth

Seekingalpha.com/article/4827295-futura-medical-plc-famdf-q2-2025-earnings-call-transcript

Roy Davis

Roy is an experienced executive with over 35 years of global experience in a variety of industries including medtech, diagnostics and technology sectors. He is currently Chairman of Inspiration Healthcare Group plc, a leading neonatal respiratory company, and Foster & Freeman Ltd (the trading name of the Galton group of companies), a leading forensic imaging manufacturer. He is also a Non-Executive Director of Futura Medical plc, a UK pharmaceutical company focussed on the sexual health market and a Senior Advisor to Moore Walker Partners, a Healthcare & Technology Advisory Services company. Roy was previously Chairman of LunglifeAI plc, Medica Group plc until its sale to IK Partners in 2023 and Chairman of Edinburgh Molecular Imaging Ltd and RAIR Health Ltd.

Before these Non-Executive roles Roy served as the Chief Executive Officer of Optos plc, a leading ophthalmology medical device business, from 2008 until June 2016 when he stepped down following the company's acquisition by Nikon Corporation. Before joining Optos, he served from 2007 as Chief Executive Officer of Gyrus Group plc, a leading medical device company, prior to its acquisition by the Olympus Corporation of Japan in 2008, having previously served as Chief Operating Officer of Gyrus from 2003 and a Non-Executive Director since the company's flotation in 1997.

Prior to this, Roy spent almost ten years with Arthur D Little, the global management consulting company, where he was vice president and global head of its operations management business. His early career included experience in the electronics, oil, and automotive sectors. Roy holds a mechanical engineering degree from the University of Southampton and an MBA from the London Business School.

Roy will become Chair of the Nomination Committee and be a member of the Renumeration and Audit Committees, effective immediately.

investments.halifax.co.uk/research-centre/news-centre/article/?id=35384152&type=rns

I ran out of space to say Tuesday that we may find out how much it cost to ouste the CO & Chair, and how much the CMO is costing in penalties due to low/no sales

After 5 years holding, I fear for Tuesday, and tomorrow. As I look back over recent months, I hovered over the sell button at 15p, and more recently at 5p. They are both now long gone.

Monday will bring out the sellers who are not willing to take the risk of the results and take the price down with it.

We know some of the headlines for Tuesday already, but the market will likely drop the price another 30-40% on Tuesday opening, as happens for all poor results in today's volatile market.

But it's what we don't know that concerns me most. Due to NDA's, there will still be no sales figures, and possibly not even geographical revenue. Previous RNS have been positive on Mexico (and their social media marketing) and also the Nordics have released positive news, but will FUM be allowed to report any facts, contractually? I doubt it.

There is only cash runway until January, this has to be addressed, but I'm not sure this will be part of H1 announcement, so may well remain another dark cloud.

So what is there to be optimistic about?

i) CEO change - I've read lots on here about good riddance to JB and the 25 years experience of the replacement. Whilst it was time for JB to go, he did a great job to take FUM from a lifetime of R&D to a commercial business, shame it didn't work out. But, his last couple of result presentations were just dreadful. Your CEO needs to be THE cheerleader for the business, there to make investors want to invest. Hopefully, Duggan will be just that on Tuesday.

(BTW, anyone bothered to check out Alexander James Hanbury DUGGAN and his 25 years experiance on Company House?)

ii) New product - The market loves Jam Tomorrow, it thrives on it, and can move the share price considerably. So, hopefully we see positive news on Intense, with a clear plan to market launch, and news of FDA submission for WD4000

iii) Market Launch - There are still gaps to fill in markets that have a license agreement in place, but not yet launched. So it would be good to have a clear plan for launch in Poland, Germany, Austria, Oman, Australia and South America. News for a partner in China is needed, but likely remains a low priority

iv) US market - Haleon have spoken about learnings from in store launches, and recently good press for their marketing partner, so, even though the sales are well below expectations, is there any evidence that things are improving? Surely, after 12 months on the shelves, the brand awareness must be improving and turning into sales

v) Other markets - there is a world outside of the US, so please beat the drum of EU, Middle East & S.America sales. I recall at a CMD, there was a rep from the company who set up the Boots deal who was waxing lyrical about Eroxon and how well it was doing and he hadn't seen such interest in all of his 25 years in the business..... bring this guy back !!!

Hopefully there are positives on Tuesday, I'm sure I'll be holding, or maybe it really is a product that doesn't work and